GlobeNewswire
-
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 novembre 2025
22/12/2025 -
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
22/12/2025 -
PracticeLink Supports the Next Generation of Clinicians with Fall 2025 First Practice Fund Scholarships
22/12/2025 -
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
22/12/2025 -
ALK – Financial calendar for the 2026 financial year
22/12/2025 -
Wholeview Wellness Joins the Lumina Therapy Alliance, Expanding Access to In-Person Addiction-Focused Psychotherapy for Employees and Their Families
22/12/2025 -
Best Sermorelin Tablet for 2026? bmiMD Platform Lists Mint Sublingual Format at $79/Month as Peptide Wellness Interest Surges Before New Year
23/12/2025 -
Best GLP-1 Gummies for 2026: Akkermansia Probiotic Supplements for Weight Loss – Industry Analysis
23/12/2025 -
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
22/12/2025 -
RxSight, Inc. Announces Chief Financial Officer Transition
22/12/2025 -
Apollomics Reports First Half 2025 Financial Results
22/12/2025 -
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
22/12/2025 -
PeopleOne Health Selected by Orlando Regional REALTOR® Association to Deliver First-of-Its-Kind Healthcare Solution for Realtors
22/12/2025 -
Omada Health to Participate in J.P. Morgan Healthcare Conference
22/12/2025 -
OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting 2025
22/12/2025 -
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
22/12/2025 -
CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025 -
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
22/12/2025 -
Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy
22/12/2025
Pages